Business Wire

Owl Labs Teams with Ingram Micro to Widen Distribution of the Meeting Owl Pro within Europe

Share

Owl Labs, the award-winning leader in immersive and collaborative video conferencing technology and services, today announced an alliance with Ingram Micro, the world’s largest distributor and provider of technology services and solutions.The new distribution agreement expands Owl Labs’ reach across Europe and strengthens Owl Labs’ presence within key European markets.

Through Owl Labs working relationship with Ingram Micro, Owl Labs will now be able to expand the reach and accessibility of its award-winning flagship product, the Meeting Owl Pro, to one centralised distribution warehouse in Straubing, Germany, and from that single point will support its supply chain into 17 distribution centers across Europe, trading across all 28 countries. Ingram Micro serves a diverse base of resellers and 2,000+ of the world’s most recognized IT and mobility technology brands.

With the rapid adoption of hybrid work and remote teams, maintaining effective communication and collaboration regardless of location is more crucial than ever. As more diverse and flexible working patterns continue to become increasingly popular, companies will need to find a better way to connect employees, whether they are in-office or at home. Companies can achieve a seamless collaborative team experience no matter where employees are located with the Meeting Owl Pro. Powered by Owl Labs’ proprietary intelligence technology, the Meeting Owl Pro automatically focuses on who is speaking in a room using audio and visual cues from its high-definition 360° camera, as well as eight microphones and tri-speakers, that have a pickup range of five meters. Through this technology the smart device is able to create a fully immersive, near face-to-face experience for all participants involved, and is also compatible with all popular video conferencing platforms.

“We are thrilled to team up with Ingram Micro, increasing our reach and presence across Europe to expand and strengthen our business. This alliance will make it easier for businesses and educational institutions based in Europe to use Owl Labs’ collaboration technology to help maintain and facilitate clear and effective communication with employees or students, no matter their location.” states Frank Weishaupt, CEO of Owl Labs. “As hybrid and flexible working rises in popularity, there is an increased demand in products and services that help productivity and allow hybrid teams to communicate effectively. We look forward to meeting this demand through our partnership with Ingram Micro.”

Owl Labs' products are used by 50,000+ companies in 156 countries across a wide array of categories, including the likes of the Ogilvy, ClearScore, Bern University of Applied Science, and Prague College. Owl Labs has been recently named AV Technology Awards Communication Technology of the Year, as well as German Design Award Winners and Red Dot Award Recipient. The Owl Labs' Meeting Owl Pro is also named in TIME's List Of The 100 Best Inventions Of 2020.

Having the ability to work from anywhere and communicate clearly and securely from everywhere is critical to the future of work,” states Joost Boon, director, Advanced Solutions, UCC Supply Chain and Business Operations, Pan Europe GmbH, Ingram Micro. “We are pleased to welcome Owl Labs to the Ingram Micro Pan Europe portfolio, and look forward to working together with our channel partners to generate greater awareness and demand for Owl Lab’s innovative and immersive video conferencing technology solutions.”

About Owl Labs
Owl Labs is a collaborative technology company revolutionizing the way we connect. Owl Labs creates deeply immersive and inclusive meeting experiences for today’s hybrid workforce and virtual classroom. The company’s flagship product, the award-winning Meeting Owl, features a wifi-enabled, 360-degree camera, mic, and speaker powered by proprietary technology with an automatic zoom that responds to who’s speaking. In 2020, the Meeting Owl Pro was named in TIME’s 100 Best Innovations.

Owl Labs continues to champion the hybrid work movement with its annual State of Remote Work Report. To learn more about Owl Labs and the full product suite and to join the Work From Anywhere Movement, please visit www.owllabs.com.

About Ingram Micro
Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables its business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and dependability that come from decades of proven relationships, set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chloe Parker
email: owluk@clarity.pr
Phone: +44 (0)7305252756

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

HiddenA line styled icon from Orion Icon Library.Eye